+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

U.S. Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028

  • ID: 5354677
  • Report
  • June 2021
  • Region: United States
  • 140 Pages
  • DPI Research
The United States Non-Invasive Prenatal Testing Market is Expected to Reach USD 2.5 Billion by 2028

FEATURED COMPANIES

  • Agilent Technologies
  • Centogene
  • GenPath
  • Illumina
  • Invitae Corporation
  • Myriad Genetics
  • MORE

The United States Non-Invasive Prenatal Testing (NIPT) market is expected to touch a valuation of USD 2.5 Billion by 2028.

The U.S. Non-Invasive Prenatal Testing market is growing with the increasing per capita income, growing interest, increase in incidences of chromosomal aneuploidies among fetus, development of advanced non-invasive prenatal testing products, rising awareness regarding non-invasive prenatal testing, rising focus on reimbursement for NIPT, increasing preference for non-invasive techniques over invasive methods and ACOG guidelines recommend NIPT for all pregnancies regardless of risk. The market shows high potential for growth in the future.

This new market report presents a comprehensive study of the entire United States non-invasive prenatal testing market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States' non-invasive prenatal testing market. The report also provides up-to-date historical market size data for the period 2015 - 2020 and an illustrative forecast to 2028 covering key market aspects like market value and volume for non-invasive prenatal testing in the United States.

This Comprehensive Report Provides:

  • To Analyse the Historical Growth in the Market Size of the United States Non-Invasive Prenatal Testing Market from 2015 to 2020.
  • To Estimate and Forecast the Market Size of the United States Non-Invasive Prenatal Testing Market from 2021 to 2028 and Growth Rate until 2028.
  • The Market Size of the United States Average Risk Non-Invasive Prenatal Testing Market with Seven Years Forecast
  • The Market Size of the United States High-Risk Non-Invasive Prenatal Testing Market with Seven Years Forecast
  • Evaluates the Number of NIPT Tests Performed in the United States with Seven Years Forecast
  • Studies the United States Number of Average Risk NIPT Tests Performed with Seven Years Forecast
  • Examines the United States Number of High-Risk NIPT Tests Performed with Seven Years Forecast
  • Assessment of Market Potential and Opportunities for this Innovation-Driven United States Non-Invasive Prenatal Testing Market with Seven Years Forecast
  • Insights into the United States Average and High-Risk Potential NIPT Tests Market with Seven Years Forecast
  • Meticulously Assesses the Overall United States Potential Non-Invasive Prenatal Testing (NIPT) Volume and Future Trends
  • Analyses of the United States Average and High-Risk Potential Number of Tests Performed with Seven Years Forecast
  • Detailed Insights into the Regulatory Framework of the United States Non-Invasive Prenatal Testing Market 
  • Features Reimbursement Patterns of the United States Non-Invasive Prenatal Testing Market 
  • Tracks Competitive Developments, Approaches, Recent Industry Developments, Mergers & Acquisitions, Collaboration Deals, Partnership Deals, Distribution, Exclusive, and Licensing Agreement
  • A Comprehensive List of the Key Players Along with the Analysis of their Current NIPT Test Portfolios, Business Overview, and Recent Development

The Leading Companies for the United States Non-Invasive Prenatal Testing Market are Listed Below:

  • Illumina
  • Natera
  • Quest Diagnostics
  • Myriad Genetics
  • Centogene
  • GenPath
  • Progenity
  • PerkinElmer
  • Yourgene Health
  • Invitae Corporation
  • Agilent Technologies
  • Ariosa Diagnostics (Roche)
  • Integrated Genetics (LabCorp)

Key Questions Answered in this Report:

  • What is the current scenario of the United States non-invasive prenatal testing market?
  • What is the total market size and forecast (until 2028) for the United States non-invasive prenatal testing market?
  • How has the potential market performed so far and how will it perform in the coming years?
  • How many NIPT tests being performed in the U.S. during 2015 - 2028?
  • What is the market size of the average risk NIPT tests in the United States?
  • What is the market size of the high-risk NIPT tests in the United States?
  • What are the key marketed NIPT tests available in the United States?
  • What are the major drivers of the United States non-invasive prenatal testing market?
  • What are the major inhibitors of the United States non-invasive prenatal testing market?
  • What is the reimbursement pattern in the United States non-invasive prenatal testing market?
  • What is the regulatory framework in the United States non-invasive prenatal testing market?
  • What are the major deals and agreement happenings in the United States non-invasive prenatal testing market?
  • Who are the top market players? What are their happenings, current developments, and scenarios?
  • How is the market predicted to develop in the future?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Agilent Technologies
  • Centogene
  • GenPath
  • Illumina
  • Invitae Corporation
  • Myriad Genetics
  • MORE

1. Executive Summary

2. United States Actual Non-Invasive Prenatal Testing Volume (Number of Tests Performed) and Forecast (2015 - 2028)
2.1 Average Risk Actual NIPT Test Volume (Number of Tests Performed) and Forecast
2.2 High-Risk Actual NIPT Test Volume (Number of Tests Performed) and Forecast

3. United States Potential Non-Invasive Prenatal Testing Volume (Number of Tests Performed) and Forecast (2015 - 2028)
3.1 Average Risk Potential NIPT Test Volume (Number of Tests Performed) and Forecast
3.2 High-Risk Potential NIPT Test Volume (Number of Tests Performed) and Forecast

4. United States Actual Non-Invasive Prenatal Testing Market Size and Forecast (2015 - 2028)
4.1 Average Risk Actual NIPT Test Market Size and Forecast
4.2 High-Risk Actual NIPT Test Market Size and Forecast

5. United States Potential Non-Invasive Prenatal Testing Market Size and Forecast (2015 - 2028)
5.1 Average Risk Potential NIPT Test Market Size and Forecast
5.2 High-Risk Potential NIPT Test Market Size and Forecast

6. United States Non-Invasive Prenatal Testing Market Growth Drivers and Challenges
6.1 Key Market Growth Drivers
6.2 Key Market Challenges

7. Non-Invasive Prenatal Testing Comparative Analysis

8. Reimbursement Environment of the United States Non-Invasive Prenatal Testing Market

9. Regulation Framework of the United States Non-Invasive Prenatal Testing Market

10. Major Deals and Agreements in the Non-Invasive Prenatal Testing Market
10.1 Collaboration Deals
10.2 Venture Capital Investment
10.3 Mergers and Acquisitions
10.4 Exclusive Agreement
10.5 Licensing Agreement
10.6 Distribution Agreement
10.7 Partnership Deals

11. Key Companies Analysis
11.1 Integrated Genetics (LabCorp)
11.1.1 Business Overview
11.1.2 Product Outlook
11.1.3 Key Developments
11.2 Yourgene Health
11.2.1 Business Overview
11.2.2 Product Outlook
11.2.3 Key Developments
11.3 Ariosa Diagnostics (Roche)
11.3.1 Business Overview
11.3.2 Product Outlook
11.3.3 Key Developments
11.4 Illumina
11.4.1 Business Overview
11.4.2 Product Outlook
11.4.3 Key Developments
11.5 Natera
11.5.1 Business Overview
11.5.2 Product Outlook
11.5.3 Key Developments
11.6 Quest Diagnostics
11.6.1 Business Overview
11.6.2 Product Outlook
11.6.3 Key Developments
11.7 Myriad Genetics
11.7.1 Business Overview
11.7.2 Product Outlook
11.7.3 Key Developments
11.8 Centogene
11.8.1 Business Overview
11.8.2 Product Outlook
11.8.3 Key Developments
11.9 Invitae Corporation
11.9.1 Business Overview
11.9.2 Product Outlook
11.9.3 Key Developments
11.10 GenPath
11.10.1 Business Overview
11.10.2 Product Outlook
11.10.3 Key Developments
11.11 Progenity
11.11.1 Business Overview
11.11.2 Product Outlook
11.11.3 Key Developments
11.12 PerkinElmer
11.12.1 Business Overview
11.12.2 Product Outlook
11.12.3 Key Developments
11.13 Agilent Technologies
11.13.1 Business Overview
11.13.2 Product Outlook
11.13.3 Key Developments

List of Tables:
Table 6-1: Maternal Age at Delivery and Risk of Down Syndrome
Table 7-1: Non-Invasive Prenatal Testing - Comparative Tests Analysis
Table 10-1: Collaboration Deals in the Non-Invasive Prenatal Testing Market
Table 10-2: Venture Capital Investment in the Non-Invasive Prenatal Testing Market
Table 10-3: Merger & Acquisition in the Non-Invasive Prenatal Testing Market
Table 10-4: Exclusive Agreement in the Non-Invasive Prenatal Testing Market
Table 10-5: Licensing Agreement in the Non-Invasive Prenatal Testing Market
Table 10-6: Distribution Agreement in the Non-Invasive Prenatal Testing Market
Table 10-7: Partnership Deals in the Non-Invasive Prenatal Testing Market

List of Figures:
Figure 2-1: United States Actual NIPT Test Volume (Thousand),2015 - 2020
Figure 2-2: United States Actual NIPT Test Volume Forecast (Thousand),2021 - 2028
Figure 2-3: United States Average Risk Actual NIPT Test Volume (Thousand),2015 - 2020
Figure 2-4: United States Average Risk Actual NIPT Test Volume Forecast (Thousand),2021 - 2028
Figure 2-5: United States High-Risk Actual NIPT Test Volume (Thousand),2015 - 2020
Figure 2-6: United States High-Risk Actual NIPT Test Volume Forecast (Thousand),2021 - 2028
Figure 3-1: United States Potential NIPT Test Volume (Thousand),2015 - 2020
Figure 3-2: United States Potential NIPT Test Volume Forecast (Thousand),2021 - 2028
Figure 3-3: United States Average Risk Potential NIPT Test Volume (Thousand),2015 - 2020
Figure 3-4: United States Average Risk Potential NIPT Test Volume Forecast (Thousand),2021 - 2028
Figure 3-5: United States High-Risk Potential NIPT Test Volume (Thousand),2015 - 2020
Figure 3-6: United States High-Risk Potential NIPT Test Volume Forecast (Thousand),2021 - 2028
Figure 4-1: United States Actual NIPT Test Market Size (Million US$),2015 - 2020
Figure 4-2: United States Actual NIPT Test Market Size Forecast (Million US$),2021 - 2028
Figure 4-3: United States Average Risk Actual NIPT Test Market Size (Million US$),2015 - 2020
Figure 4-4: United States Average Risk Actual NIPT Test Market Size Forecast (Million US$),2021 - 2028
Figure 4-5: United States High-Risk Actual NIPT Test Market Size (Million US$),2015 - 2020
Figure 4-6: United States High-Risk Actual NIPT Test Market Size Forecast (Million US$),2021 - 2028
Figure 5-1: United States Potential NIPT Test Market Size (Million US$),2015 - 2020
Figure 5-2: United States Potential NIPT Test Market Size Forecast (Million US$),2021 - 2028
Figure 5-3: United States Average Risk Potential NIPT Test Market Size (Million US$),2015 - 2020
Figure 5-4: United States Average Risk Potential NIPT Test Market Size Forecast (Million US$),2021 - 2028
Figure 5-5: United States High-Risk Potential NIPT Test Market Size (Million US$),2015 - 2020
Figure 5-6: United States High-Risk Potential NIPT Test Market Size Forecast (Million US$),2021 - 2028

Note: Product cover images may vary from those shown

Loading
LOADING...

  • Agilent Technologies
  • Ariosa Diagnostics (Roche)
  • Centogene
  • GenPath
  • Illumina
  • Integrated Genetics (LabCorp)
  • Invitae Corporation
  • Myriad Genetics
  • Natera
  • PerkinElmer
  • Progenity
  • Quest Diagnostics
  • Yourgene Health
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll